Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CRNX

Crinetics Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CRNX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-5.05

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:56 UTC.

What Crinetics Pharmaceuticals, Inc. does

The company is a pharmaceutical firm focused on discovering and developing treatments for endocrine diseases and endocrine-related tumors by targeting GPCRs with small-molecule drugs tailored to specific receptors. Its approved product, PALSONIFY (paltusotine), is an oral treatment for adults with acromegaly who have not adequately responded to surgery or cannot have surgery. The company has a pipeline of additional programs in clinical development, including atumelnant for certain endocrine conditions and CRN09682 for neuroendocrine tumors and related solid tumors.

Summarized from Crinetics Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

CRNX no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-5.05

Revenue, margins & earnings

FY2021: net loss $108M on revenue $1M$1MFY2021FY2022: net loss $164M on revenue $5M$5MFY2022FY2023: net loss $215M on revenue $4M$4MFY2023FY2024: net loss $298M on revenue $1M$1MFY2024FY2025: net loss $465M on revenue $8M$8MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-01
  • 2026-09-01DirectorStock Option (Right to Buy)Returned to company-17,500$1.13M
  • 2026-09-01DirectorReturned to company-16,300$1.39M
  • 2026-09-01DirectorStock Option (Right to Buy)Returned to company-12,500$503.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Crinetics Pharmaceuticals, Inc. do?

The company is a pharmaceutical firm focused on discovering and developing treatments for endocrine diseases and endocrine-related tumors by targeting GPCRs with small-molecule drugs tailored to specific receptors.

When did CRNX last file with the SEC?

Crinetics Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:56 UTC. This page is also available as JSON at /api/data?ticker=CRNX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CRNX and 5,000+ tickers.

Create a free account — keep CRNX
For your agent
GET /api/data?ticker=CRNX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt